AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02267278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat
Description: Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
Study NCT02267278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
Study NCT01201707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty
Description: In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.
Study NCT01201707 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Observation
Description: Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
Study NCT03108625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
Study NCT02119286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
Study NCT02119286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
Study NCT02119286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
Study NCT02119286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The matching placebo DPI identical in appearance to the inhaler containing active study medication.
Study NCT00554307 — intervention group
Intervention type: DEVICE
Intervention: INVOS Cerebral/Somatic oximeter
Description: Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
Study NCT02067429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limbal Relaxing Incisions
Study NCT02067429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Intraocular Lens
Study NCT04076384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Determination
Description: Structured team-based consultations
Study NCT04076384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard consultations
Study NCT02390141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP4207
Study NCT02390141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04271020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift
Description: The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
Study NCT02852642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Plyometric training
Study NCT00186758 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -
Study NCT00186758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -
Study NCT03449836 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius 24SMBc + Strept. oralis 89a
Description: nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a
Study NCT03449836 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone + mometasone
Description: nasal spray based on fluticasone + mometasone
Study NCT03449836 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: nasal spray based on isotonic solution
Study NCT00429156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home non-invasive ventilation
Description: Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
Study NCT00429156 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Home non-invasive ventilation (sham)
Description: Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
Study NCT04191837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure treatment group
Description: Subjects in the self-administered acupressure exercise group will receive two training sessions (2 hours each, 1-week apart). The self-administered acupressure treatment protocol was developed based on Chinese medicine meridian theory by previous studies and modified. The acupoints are indicated for knee pain and have been commonly used and tested for feasibility in pilot study. The training will be conducted in a group format with 4-6 subjects per group. Each subject will then receive a handout and an acupressure log. They will be told to perform the self-acupressure twice per day for 12 weeks.The capability of participants for self-administered acupressure will be inspected by the instructor with a competency checklist in each session. And a demonstration video will be sent to the participants via WhatsApp for their reference at home.
Study NCT04191837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee health education control group
Description: Subjects in the health education control group will receive knowledge related to knee OA symptom management. The health education will be conducted in a talk format for 2 hours for two sessions. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR and reviewed. Subjects in knee health education group will be told to follow the knee health instruction for 12 weeks.
Study NCT01770392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: single dose administration
Study NCT01770392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: single dose once daily for 7 days
Study NCT01770392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: single dose administration
Study NCT03858192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal surgery procedure
Description: Elective admission for colorectal surgery
Study NCT03858192 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery
Description: Emergency admission necessitating emergency surgery
Study NCT03858192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Treatment for infection and reason for admission
Study NCT02434432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy selected by mothers
Description: mothers' choice of music
Study NCT02434432 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music therapy recorded lullaby
Description: recorded lullaby
Study NCT04350320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: standard therapy for COVID-19 according to the stablished hospital protocols.
Study NCT04350320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for COVID-19 according to the stablished hospital protocols.
Description: standard therapy for COVID-19 according to the stablished hospital protocols.
Study NCT04350320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy for COVID-19 according to the stablished hospital protocols.
Description: standard therapy for COVID-19 according to the stablished hospital protocols.
Study NCT02775708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillcam endoscopy system
Study NCT00939120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4mg
Description: 1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
Study NCT00939120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
Study NCT00939120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-randomization Dutasteride
Description: All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
Study NCT00939120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pre-randomization Dutasteride
Description: All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
Study NCT03446911 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Description: Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy.
Study NCT03446911 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: SABR + pembrolizumab
Description: Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy + 2 rounds of pembrolizumab
Study NCT04145583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
Study NCT04145583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole +HSK3486
Description: Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
Study NCT02017886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri DSM 17938/ATCC PTA
Description: L. reuteri DSM 17938/ATCC PTA twice daily for three weeks
Study NCT02017886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily for three weeks
Study NCT03248050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy encouraged to promote call centre use to clients
Description: The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
Study NCT01874873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Study NCT02766595 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hyperventilation while sitting up during routine EEG
Description: Child will be asked to perform hyperventilation while lying down as well as while sitting up
Study NCT03461185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TK Inhibitor
Description: EGFR-TKIs include but are not limited erlotinib, gefitinib
Study NCT03461185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TK Inhibitor
Description: EGFR-TKIs include but are not limited erlotinib, gefitinib
Study NCT03461185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Angiogenic Drugs
Description: Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
Study NCT03255811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.
Study NCT04188002 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Physical Activity
Description: 4 tailored newsletters focused on improving healthy diet and physical activity delivered at weekly intervals.
Study NCT04770688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib, 80mg, QD, p.o.
Study NCT04770688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: (Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle.
Study NCT01543919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study NCT01543919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study NCT01543919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study NCT04188002 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: 4 non-tailored newsletters focused on issues relevant to cancer survivors (e.g. returning to work)
Study NCT03292393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial reward
Description: In contingency management, financial rewards are contingent upon an individual changing behavior. In our study, financial incentives are contingent upon group behavioral changes.. In the intervention phase participants will be randomly assigned to one of the three treatment arms and they will receive the financial incentive that corresponds to their treatment arm. Data will be collected for four months and all participants will continue receiving a compensation for participation
Study NCT03292393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social norms
Description: To build social norms the study adds a group component to a contingency management model. In contingency management, financial rewards are contingent upon an individual changing behavior. Social norms are expected to emerge as a result of the designed group contingency management, monthly-facilitated meetings at a local clinic, and daily basis interaction through social media. The intervention will build social norms that improve medication adherence of each member of a group. A three-arm randomize trial is designed to test this hypothesis. Hypertensive patients will be randomly assigned to a group contingency management (GCM) arm, an individual contingency management (ICG) arm, or a control arm.
Study NCT03292393 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Home Blood Pressure Monitoring
Description: Participants will be reminded that they will receive and learn how to use a Home Blood Pressure Monitor (HBPM) device that participant will keep for the duration of the study
Study NCT03292393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Blood Pressure Monitoring
Description: Participants will be reminded that they will receive and learn how to use a Home Blood Pressure Monitor (HBPM) device that participant will keep for the duration of the study
Study NCT03292393 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Medication adherence assessment
Description: Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
Study NCT01543919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Study NCT03292393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medication adherence assessment
Description: Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
Study NCT01324687 — intervention group
Intervention type: OTHER
Intervention: Telemedicine care
Description: Availability of telemedicine
Study NCT04197024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise capacity test
Description: Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.
Study NCT04197024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise capacity test in virtual reality
Description: Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.
Study NCT00444470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid.
Study NCT00444470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo.
Study NCT03543670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oncoxin-Viusid
Description: Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).
Study NCT04016688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB and TAP block
Description: bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side.
Study NCT00970268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
Study NCT00970268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
Study NCT01106482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serology blood draw
Description: Blood draw only, no vaccine
Study NCT01476735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual preparation for colonoscopy
Description: The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy